Christina Voelkel-Johnson Department of Microbiology & Immunology Medical University of South Carolina Biography Publications Institution JoVE Articles Christina Voelkel-Johnson has not added a biography. If you are Christina Voelkel-Johnson and would like to personalize this page please email our Author Liaison for assistance. Publications Targeting Sphingosine Kinase Induces Apoptosis and Tumor Regression for KSHV-associated Primary Effusion Lymphoma Molecular Cancer Therapeutics. Oct, 2013 | Pubmed ID: 24140934 Inner Ear Supporting Cells Protect Hair Cells by Secreting HSP70 The Journal of Clinical Investigation. Aug, 2013 | Pubmed ID: 23863716 Histone Deacetylase Inhibitors Restore Cell Surface Expression of the Coxsackie Adenovirus Receptor and Enhance CMV Promoter Activity in Castration-resistant Prostate Cancer Cells Prostate Cancer. 2012 | Pubmed ID: 22288017 TRAIL-mediated Signaling in Prostate, Bladder and Renal Cancer Nature Reviews. Urology. Aug, 2011 | Pubmed ID: 21670755 T Cells Expanded in Presence of IL-15 Exhibit Increased Antioxidant Capacity and Innate Effector Molecules Cytokine. Aug, 2011 | Pubmed ID: 21602054 Adenoviral Infectivity of Exfoliated Viable Cells in Urine: Implications for the Detection of Bladder Cancer BMC Cancer. 2011 | Pubmed ID: 21569442 Sorafenib Activates CD95 and Promotes Autophagy and Cell Death Via Src Family Kinases in Gastrointestinal Tumor Cells Molecular Cancer Therapeutics. Aug, 2010 | Pubmed ID: 20682655 Vorinostat and Sorafenib Increase CD95 Activation in Gastrointestinal Tumor Cells Through a Ca(2+)-de Novo Ceramide-PP2A-reactive Oxygen Species-dependent Signaling Pathway Cancer Research. Aug, 2010 | Pubmed ID: 20631069 17-allylamino-17-demethoxygeldanamycin and MEK1/2 Inhibitors Kill GI Tumor Cells Via Ca2+-dependent Suppression of GRP78/BiP and Induction of Ceramide and Reactive Oxygen Species Molecular Cancer Therapeutics. May, 2010 | Pubmed ID: 20442308 Polymer-enhanced Adenoviral Transduction of CAR-negative Bladder Cancer Cells Molecular Pharmaceutics. Sep-Oct, 2009 | Pubmed ID: 19655763 Inhibition of Superoxide Generation Upon T-cell Receptor Engagement Rescues Mart-1(27-35)-reactive T Cells from Activation-induced Cell Death Cancer Research. Aug, 2009 | Pubmed ID: 19638595 Oxidative Stress Sensitizes Bladder Cancer Cells to TRAIL Mediated Apoptosis by Down-regulating Anti-apoptotic Proteins The Journal of Urology. Sep, 2009 | Pubmed ID: 19625063 Oxidative Stress and Lymphocyte Persistence: Implications in Immunotherapy Advances in Cancer Research. 2009 | Pubmed ID: 19595310 The Role of Protein Synthesis in Cell Cycling and Cancer Molecular Oncology. Dec, 2009 | Pubmed ID: 19546037 Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95-dependent and -independent Mechanisms Molecular Pharmacology. Aug, 2009 | Pubmed ID: 19483104 MDA-7/IL-24-induced Cell Killing in Malignant Renal Carcinoma Cells Occurs by a Ceramide/CD95/PERK-dependent Mechanism Molecular Cancer Therapeutics. May, 2009 | Pubmed ID: 19417161 Cancer Biology & Therapy. Jan, 2009 | Pubmed ID: 19127121 Transformation, Translation and TRAIL: an Unexpected Intersection Cytokine & Growth Factor Reviews. Apr, 2008 | Pubmed ID: 18353705 Doxorubicin Generates a Proapoptotic Phenotype by Phosphorylation of Elongation Factor 2 Free Radical Biology & Medicine. Nov, 2007 | Pubmed ID: 17893044 Illuminating TRAIL Gene Therapy Cancer Biology & Therapy. Nov, 2006 | Pubmed ID: 17204862 Targeting the Short Form of CFLIP by RNA Interference is Sufficient to Enhance TRAIL Sensitivity in PC3 Prostate Carcinoma Cells Cancer Biology & Therapy. Dec, 2006 | Pubmed ID: 17106251 Resistance to TRAIL is Associated with Defects in Ceramide Signaling That Can Be Overcome by Exogenous C6-ceramide Without Requiring Down-regulation of Cellular FLICE Inhibitory Protein Molecular Cancer Therapeutics. Sep, 2005 | Pubmed ID: 16170023 Doxorubicin Increases the Effectiveness of Apo2L/TRAIL for Tumor Growth Inhibition of Prostate Cancer Xenografts BMC Cancer. Jan, 2005 | Pubmed ID: 15638938 In Vitro Efficacy of Fas Ligand Gene Therapy for the Treatment of Bladder Cancer Cancer Gene Therapy. Jan, 2005 | Pubmed ID: 15514684 Enhanced Apoptosis of Glioma Cell Lines is Achieved by Co-delivering FasL-GFP and TRAIL with a Complex Ad5 Vector Cancer Gene Therapy. Nov, 2003 | Pubmed ID: 14605667 An Antibody Against DR4 (TRAIL-R1) in Combination with Doxorubicin Selectively Kills Malignant but Not Normal Prostate Cells Cancer Biology & Therapy. May-Jun, 2003 | Pubmed ID: 12878867 Doxorubicin Pretreatment Sensitizes Prostate Cancer Cell Lines to TRAIL Induced Apoptosis Which Correlates with the Loss of C-FLIP Expression Cancer Biology & Therapy. Sep-Oct, 2002 | Pubmed ID: 12496481 Resistance of Prostate Cancer Cells to Soluble TNF-related Apoptosis-inducing Ligand (TRAIL/Apo2L) Can Be Overcome by Doxorubicin or Adenoviral Delivery of Full-length TRAIL Cancer Gene Therapy. Feb, 2002 | Pubmed ID: 11857034 An Orthotopic Bladder Cancer Model for Gene Delivery Studies Laura Kasman1, Christina Voelkel-Johnson1 1Department of Microbiology & Immunology, Medical University of South Carolina JoVE 50181 Medicina Dissection of Adult Mouse Utricle and Adenovirus-mediated Supporting-cell Infection Carlene S. Brandon1, Christina Voelkel-Johnson2, Lindsey A. May3, Lisa L. Cunningham3 1Department of Pathology and Laboratory Medicine, Medical University of South Carolina, 2Department of Microbiology & Immunology, Medical University of South Carolina, 3National Institute on Deafness and Other Communication Disorders, National Institutes of Health JoVE 3734 Neurociência
An Orthotopic Bladder Cancer Model for Gene Delivery Studies Laura Kasman1, Christina Voelkel-Johnson1 1Department of Microbiology & Immunology, Medical University of South Carolina JoVE 50181 Medicina
Dissection of Adult Mouse Utricle and Adenovirus-mediated Supporting-cell Infection Carlene S. Brandon1, Christina Voelkel-Johnson2, Lindsey A. May3, Lisa L. Cunningham3 1Department of Pathology and Laboratory Medicine, Medical University of South Carolina, 2Department of Microbiology & Immunology, Medical University of South Carolina, 3National Institute on Deafness and Other Communication Disorders, National Institutes of Health JoVE 3734 Neurociência